Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTV NASDAQ:CTNM NASDAQ:DBVT NYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$3.15-0.3%$2.47$1.47▼$17.31$77.18MN/A67,823 shs35,232 shsCTNMContineum Therapeutics$10.45+4.0%$6.00$3.35▼$20.30$281.82M1.04253,879 shs155,702 shsDBVTDBV Technologies$9.58+0.8%$9.80$2.20▼$12.78$260.32M-0.5835,644 shs21,453 shsVORVor Biopharma$1.97-2.0%$1.96$0.13▼$3.29$249.57M2.067.79 million shs3.65 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics-0.32%+9.38%+5.70%+60.71%-71.18%CTNMContineum Therapeutics+3.98%+5.13%+73.88%+188.67%-43.45%DBVTDBV Technologies+1.48%-4.20%+1.91%+15.42%+120.23%VORVor Biopharma-1.99%-9.22%-10.86%+885.49%+129.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTVArtiva Biotherapeutics3.1537 of 5 stars3.50.00.00.02.92.51.3CTNMContineum Therapeutics3.3534 of 5 stars3.65.00.00.03.50.80.6DBVTDBV Technologies3.3744 of 5 stars3.45.00.00.02.52.50.6VORVor Biopharma1.9498 of 5 stars3.30.00.00.01.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTVArtiva Biotherapeutics 3.00Buy$17.00439.68% UpsideCTNMContineum Therapeutics 3.17Buy$22.75117.70% UpsideDBVTDBV Technologies 2.80Moderate Buy$14.7553.97% UpsideVORVor Biopharma 2.56Moderate Buy$6.07207.95% UpsideCurrent Analyst Ratings BreakdownLatest ARTV, CTNM, VOR, and DBVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025CTNMContineum TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$20.00 ➝ $21.008/14/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.006/30/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$3.006/26/2025DBVTDBV TechnologiesLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/26/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$21.006/26/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Outperform6/20/2025CTNMContineum TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform6/11/2025ARTVArtiva BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$12.005/29/2025DBVTDBV TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell$7.25(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTVArtiva Biotherapeutics$250K307.82N/AN/A$6.10 per share0.52CTNMContineum Therapeutics$50M5.86N/AN/A$6.11 per share1.71DBVTDBV Technologies$4.15M63.23N/AN/A$3.15 per share3.04VORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTVArtiva Biotherapeutics-$65.37MN/A0.00N/AN/AN/A-42.60%-37.76%11/11/2025 (Estimated)CTNMContineum Therapeutics-$42.26M-$2.20N/AN/AN/AN/A-29.75%-28.08%11/5/2025 (Estimated)DBVTDBV Technologies-$113.92M-$4.77N/AN/AN/A-3,220.49%-287.15%-138.83%11/5/2025 (Estimated)VORVor BiopharmaN/A-$13.66N/AN/AN/AN/AN/AN/AN/ALatest ARTV, CTNM, VOR, and DBVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ARTVArtiva Biotherapeutics-$0.84-$0.87-$0.03-$0.87N/AN/A8/5/2025Q2 2025CTNMContineum Therapeutics-$0.56-$0.62-$0.06-$0.62$7.50 millionN/A7/29/2025Q2 2025DBVTDBV Technologies-$0.21-$1.55-$1.34-$1.55$0.64 million$1.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/ACTNMContineum TherapeuticsN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTVArtiva BiotherapeuticsN/A13.8413.84CTNMContineum TherapeuticsN/A24.5124.51DBVTDBV TechnologiesN/A2.452.45VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTVArtiva BiotherapeuticsN/ACTNMContineum TherapeuticsN/ADBVTDBV Technologies71.74%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipARTVArtiva Biotherapeutics21.40%CTNMContineum Therapeutics11.30%DBVTDBV Technologies1.44%VORVor Biopharma0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTVArtiva Biotherapeutics8124.43 million19.20 millionN/ACTNMContineum Therapeutics3128.04 million24.87 millionN/ADBVTDBV Technologies8027.39 million27.00 millionOptionableVORVor Biopharma140126.68 million65.45 millionNot OptionableARTV, CTNM, VOR, and DBVT HeadlinesRecent News About These CompaniesVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 284,190 SharesAugust 28 at 8:06 AM | insidertrades.comVor Biopharma shares rise after collaborator’s IgAN therapy meets Phase 3 endpointAugust 28 at 6:58 AM | msn.comTelitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA NephropathyAugust 27 at 8:00 AM | globenewswire.comVor Biopharma Inc. (NYSE:VOR) Receives $6.07 Average PT from BrokeragesAugust 27 at 2:55 AM | americanbankingnews.comVor Bio to Participate in Upcoming Investor ConferencesAugust 26, 2025 | globenewswire.comVor Biopharma Inc. (NYSE:VOR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsAugust 26, 2025 | marketbeat.comVor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 19, 2025 | finanznachrichten.deQ3 EPS Estimates for Vor Biopharma Reduced by HC WainwrightAugust 19, 2025 | marketbeat.comVor Biopharma Q3 EPS Forecast Decreased by HC WainwrightAugust 19, 2025 | americanbankingnews.comVor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 18, 2025 | globenewswire.comAnalysts Set Expectations for Vor Biopharma FY2028 EarningsAugust 17, 2025 | marketbeat.comWedbush Brokers Boost Earnings Estimates for Vor BiopharmaAugust 17, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Receives "Buy" Rating from HC WainwrightAugust 16, 2025 | marketbeat.comVor Biopharma Shares Soar on Positive Results for Autoimmune-Disorder TreatmentAugust 13, 2025 | marketwatch.comVor says drug licensed from RemeGen succeeded in Sjögren’s studyAugust 13, 2025 | finance.yahoo.comVor Bio Rallies On Strong Data For Autoimmune Drug CandidateAugust 13, 2025 | benzinga.comTelitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL InhibitorAugust 13, 2025 | globenewswire.comVor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial OfficerAugust 4, 2025 | globenewswire.comVor Biopharma (NYSE:VOR) Trading Down 2.9% - Time to Sell?July 30, 2025 | marketbeat.comVor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 30, 2025 | marketbeat.comVor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to BoardJuly 29, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025Big Rallies Brewing? 3 Analyst Favorites to Watch CloselyBy Nathan Reiff | August 18, 2025Big Analyst Revisions Could Be Ahead for SoFi StockBy Gabriel Osorio-Mazilli | August 26, 2025Shopify’s Risk-Reward Profile Is Suddenly Red HotBy Sam Quirke | August 22, 2025ARTV, CTNM, VOR, and DBVT Company DescriptionsArtiva Biotherapeutics NASDAQ:ARTV$3.15 -0.01 (-0.32%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.16 +0.01 (+0.32%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Contineum Therapeutics NASDAQ:CTNM$10.45 +0.40 (+3.98%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$10.48 +0.03 (+0.24%) As of 08/29/2025 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.DBV Technologies NASDAQ:DBVT$9.58 +0.08 (+0.84%) Closing price 08/29/2025 03:58 PM EasternExtended Trading$9.58 0.00 (0.00%) As of 08/29/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Vor Biopharma NYSE:VOR$1.97 -0.04 (-1.99%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.00 +0.03 (+1.27%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
